Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Subscribe To Our Newsletter & Stay Updated